On the stock market since 2021, it operates in the world of health and science. It has 57 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $197.3M in the vault; even if every debt were paid off, $197.3M would remain.
A loss of $93.5M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.
On our five-subject report card, PRDS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: PRDS is a high-risk stock — not yet profitable, and its future rides on its product catching on.